Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 133 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Gastrostomy Tube Clear all
Completed Not applicable Interventional Results available

Role of Glucagon-Like Peptide-1 in Postprandial Hypoglycemia

NCT01162499
View directory record Official record
Conditions
Postprandial Hypoglycemia
Interventions
Exendin-(9-39), Vehicle
Drug · Other
Lead sponsor
Diva De Leon
Other
Eligibility
6 Months to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Comparison of Levothyroxine Formulation in Hypothyroid Patients With Enteral Feeding

NCT04878614
View directory record Official record
Conditions
Hypothyroidism
Interventions
Levothyroxine Tablet, Levothyroxine Sodium
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Recruiting Phase 3 Interventional

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

NCT06172296
View directory record Official record
Conditions
Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dinutuximab, Doxorubicin, Echocardiography Test, Etoposide, FDG-Positron Emission Tomography and Computed Tomography Scan, Hematopoietic Cell Transplantation, Irinotecan, Isotretinoin, Leukapheresis, Magnetic Resonance Imaging, Melphalan, Multigated Acquisition Scan, Radiation Therapy, Radionuclide Imaging, Survey Administration, Temozolomide, Thiotepa, Topotecan, Tumor Resection, Vincristine
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
158
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 127 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

NCT00360568
View directory record Official record
Conditions
Dyskinesias, Parkinson's Disease, Severe Motor Fluctuations
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
16
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome

NCT04901546
View directory record Official record
Conditions
Esophageal Atresia
Interventions
Patient's own saliva
Other
Lead sponsor
Stanford University
Other
Eligibility
Up to 3 Months
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Not listed Phase 2 Interventional

A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

NCT03561259
View directory record Official record
Conditions
Neuroblastoma, Neuroectodermal Tumors, Neoplasms
Interventions
131I-MIBG, 131-MIBG + Vorinostat
Drug
Lead sponsor
Jubilant DraxImage Inc.
Industry
Eligibility
1 Year and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
21
States / cities
Palo Alto, California • San Francisco, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Suspended Phase 1Phase 2 Interventional

Vitamin D and Bone Homeostasis in Ortho Polytrauma Patients

NCT03066817
View directory record Official record
Conditions
Vitamin D Deficiency, Polytrauma, Orthopedic Disorder
Interventions
Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL], Propylene Glycol
Drug
Lead sponsor
New York City Health and Hospitals Corporation
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Phase 2 Interventional Results available

Long-term Outcome of N-Carbamylglutamate Treatment in Propionic Acidemia and Methylmalonic Acidemia

NCT01597440
View directory record Official record
Conditions
Propionic Acidemia, Methylmalonic Acidemia
Interventions
N-carbamylglutamate, Standard of Care
Drug · Other
Lead sponsor
Mendel Tuchman
Other
Eligibility
1 Hour to 4 Weeks
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
7
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Confirming Proper Replacement of Dislodged Gastrostomy Tubes in Pediatric Patients

NCT04331873
View directory record Official record
Conditions
Gastrostomy Tube Site Complication, Gastrostomy Complications
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
University of Tennessee
Other
Eligibility
0 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Not listed No phase listed Observational

Single-center, Feasibility Study to Evaluate the Use and Safety of the Percutaneous Ultrasound Gastrostomy Technique

NCT03956277
View directory record Official record
Conditions
Gastrostomy
Interventions
PUG
Device
Lead sponsor
CoapTech
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Recruiting Phase 1 Interventional

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

NCT07199465
View directory record Official record
Conditions
Cytomegalovirus Prophylaxis
Interventions
Letermovir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

NCT03650452
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions
TAK-935, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 17 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
15
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse

NCT07437963
View directory record Official record
Conditions
Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Dinutuximab, Echocardiography Test, FDG-Positron Emission Tomography, Iberdomide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nuclear Radiology Imaging Procedure, Sargramostim, Topotecan
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
2
States / cities
Oakland, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Saracatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00513435
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
saracatinib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Mic-Key Versus Mini One Family Preference Comparison

NCT03041649
View directory record Official record
Conditions
Gastroesophageal Reflux, Feeding Disorder, Family Satisfaction
Interventions
GT button change - Mic-Key, GT button change - Mini One
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Day to 5 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Extension Study for Subjects Previously Enrolled in Triheptanoin Studies

NCT02214160
View directory record Official record
Conditions
Carnitine Palmitoyltransferase (CPT I or CPT II) Deficiency, Very Long Chain Acyl-CoA Dehydrogenase (VLCAD) Deficiency, Long-chain 3-hydroxy-acyl-CoA Dehydrogenase (LCHAD) Deficiency, Trifunctional Protein (TFP) Deficiency, Carnitine-acylcarnitine Translocase (CACT) Deficiency
Interventions
UX007
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
6 Months and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Not applicable Interventional

Utilization of Negative Pressure Suction to Reduce Aspiration in Oropharyngeal Dysphagia

NCT03368079
View directory record Official record
Conditions
Oropharyngeal Dysphagia
Interventions
Negative Pressure Suction Catheter
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects

NCT00660387
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa carbidopa intestinal gel (LCIG), Placebo Gel, Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets, Placebo (PBO) oral capsules, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Birmingham, Alabama • Fountain Valley, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

NCT00507767
View directory record Official record
Conditions
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Salivary Gland Squamous Cell Carcinoma, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
dasatinib, pharmacological study, laboratory biomarker analysis
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 26, 2026, 8:27 AM EDT
Recruiting Phase 2 Interventional

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

NCT06023641
View directory record Official record
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim
Drug · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 22 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2037
U.S. locations
3
States / cities
Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Completed Phase 2 Interventional Results available

A Multicenter, Open-label, Pilot Study of Soticlestat (TAK-935/OV935) in Participants With 15Q Duplication Syndrome (Dup 15q) or Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (ARCADE STUDY)

NCT03694275
View directory record Official record
Conditions
15q Duplication Syndrome, CDKL5 Deficiency Disease
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Los Angeles, California • Aurora, Colorado • Norcross, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Role of Nutrient Transit in Hyperinsulinemic Hypoglycemia

NCT04615546
View directory record Official record
Conditions
Post-Bariatric Hypoglycemia
Interventions
Use of Continuous Glucose Monitor (CGM), Use of "Cardea Solo" monitoring
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Not applicable Interventional

A Randomized, Pilot Study Comparing Cost Effectiveness on Two Commercially Available Gastric Feeding Tubes

NCT04030871
View directory record Official record
Conditions
Long Term Enteral Tube Feeding
Interventions
Capsule Dome G-Tube, Balloon Bolus feeding tube
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 26, 2026, 8:27 AM EDT
Terminated Phase 2 Interventional Results available

Self-Propelled Percutaneous Endoscopic GastroJejunostomy (PEG-J)

NCT01551095
View directory record Official record
Conditions
GERD
Interventions
PEGJ tube
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 26, 2026, 8:27 AM EDT